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Abstract: Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac
hypertrophy, with age. This remodeling, however, is intensified under stress and pathological
conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal
cardiac output in times of need; however, chronic cardiac hypertrophy may lead to heart failure and
death. MicroRNAs (miRNAs) are known to have a role in the regulation of cardiac hypertrophy. This
paper reviews recent advances in the field of miRNAs and cardiac hypertrophy, highlighting the
latest findings for targeted genes and involved signaling pathways. By targeting pro-hypertrophic
genes and signaling pathways, some of these miRNAs alleviate cardiac hypertrophy, while others
enhance it. Therefore, miRNAs represent very promising potential pharmacotherapeutic targets for
the management and treatment of cardiac hypertrophy.
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1. Introduction
The heart undergoes adaptive remodeling with age, which is exacerbated by stress and pathological
stimuli, subsequently leading to cardiovascular diseases [1,2]. Cardiac hypertrophy is a form
of remodeling characterized by the enlargement of cardiomyocytes without an increase in their
number. As the heart increases in size, the ventricles are enlarged, and the workload pressure on the
ventricular walls decreases [1,3,4]. This helps in maintaining cardiac output efficiency under stress and
pathological conditions.
Hypertrophy is classified as a physiological or pathological process, depending on the stimuli
and the underlying molecular mechanisms [4,5]. Physiological hypertrophy normally occurs during
pregnancy, infant growth, and athletic activities [6]. On the other hand, pathological hypertrophy,
which if untreated can lead to heart failure and death, is triggered by conditions including hypertension,
myocardial infarction, obesity, and diabetes [7]. Hallmarks of pathological cardiac hypertrophy include
apoptosis, fibrosis, and the upregulation of fetal cardiac gene expression [7,8]. Based on the morphology
of cardiomyocytes, cardiac hypertrophy is characterized as concentric or eccentric. Concentric cardiac
hypertrophy is defined as a reduction in ventricular dimension and an increase in cardiomyocyte
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thickness-to-length ratio, whereas in eccentric hypertrophy, cardiomyocytes are lengthened and the
ventricular chamber is widened [9,10].
Cardiac hypertrophy is a target of several therapeutic approaches, including pharmacological,
dietary supplements, and stem cell and cardiac regeneration, as well as RNA-based therapies [11,12].
A particular RNA-based therapy using microRNAs has gained attention in recent years, due to its
regulation of both cardiac physiology and pathology [13,14]. Although some microRNAs exhibit a
therapeutic role against cardiac hypertrophy, others have been shown to promote hypertrophy [15].
2. MicroRNAs (miRNAs)
MicroRNAs (miRNAs) are small, non-coding RNAs approximately 20 to 22 nucleotides in length.
They are vital regulators of several intracellular signaling pathways, which might explain why they are
evolutionary conserved. They play a master role in regulating gene expression. Through an imperfect
base pairing with their target mRNA, a single miRNA can consequently regulate the expression of more
than 100 different transcripts, thus altering up to 60% of protein-encoding genes at the translational
level [16–18]. MiRNAs originate from long primary transcripts, which are cleaved in the nucleus by
Drosha, a class 2 ribonuclease III, into miRNA precursors (pre-miRNAs) [19,20]. Pre-miRNAs are
then transported to the cytoplasm, to be cleaved by the endonuclease Dicer forming double-stranded
miRNAs [21]. One of the strands, known as the guide strand, binds to an RNA-induced silencing
complex (RISC), which uses it to bind to the target gene by base pairing [22].
Through studying miRNA–3′untranslated region (UTR) interactions or gain/loss-of-function,
miRNAs were found to regulate the expression of genes related to cardiovascular disease. In this regard,
different miRNAs have been implicated in cardiac arrhythmia [23], myocardial infarction [24–26],
valvular heart disease [27], and genetically inherited cardiomyopathy [28,29]. In addition, it is well
established that miRNAs are involved in different routes of cardiac remodeling (Figure 1) [30–35].
MiRNAs act as positive or negative regulators of cardiac hypertrophy by targeting pro-hypertrophic
signaling pathways, such as calcium signaling and cell cycle-related pathways. In our review, we aim
to focus on majorly studied anti-hypertrophic and pro-hypertrophic miRNAs, as well as recently
investigated miRNAs, by reviewing “microRNAs or miRNAs and cardiac hypertrophy” related articles
on PubMed. We describe the role of miRNAs and their dysregulation in mediating cardiac hypertrophy.
We also provide a detailed and critical discussion of their targeted pathways and the underlying
mechanisms involved in cardiac hypertrophy, with the goal of uncovering the incremental insights
into their potential as therapeutic agents.
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Figure 1. MicroRNAs (miRNAs) play a role in physiological and pathological cardiac remodeling. 
Some miRNAs have a protective role against cardiovascular diseases, whereas others promote 
extensive cardiac remodeling, leading to disease. The red color indicates miRNAs that negatively 
regulate cardiac remodeling. The green color indicates miRNAs having a positive regulatory role. 
Figure 1. MicroRNAs (miRNAs) play a role in physiological and pathological cardiac remodeling.
Some miRNAs have a protective role against cardiovascular diseases, whereas others promote extensive
cardiac remodeling, leading to disease. The red color indicates miRNAs that negatively regulate cardiac
remodeling. The green color indicates miRNAs having a positive regulatory role.
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3. MicroRNAs that Attenuate Cardiac Hypertrophy
3.1. MiR-1
MiR-1, a muscle-specific miRNA, is abundantly expressed in the heart, and plays a protective role
against cardiac hypertrophy by targeting a number of pro-hypertrophic signaling pathways [36].
Calcium signaling is a known pro-hypertrophic pathway, where an increase in intracellular Ca2+
levels acts as a signal for hypertrophy by increasing cardiac output [37]. The calcium-dependent
serine/threonine protein phosphatase, calcineurin, induces hypertrophy by acting through the
transcription factor nuclear factor of activated T cells (NFATC) 3 [38–40]. In human heart tissue
samples and mice cardiomyocytes, overexpression of miR-1 ameliorated cardiac hypertrophy by
decreasing the expression NFATC3. This was confirmed by a reduction in the cell surface area of
cardiomyocytes and a decrease in the levels of beta-myosin heavy chains (β-MHCs), a marker of
cardiac hypertrophy (Figure 2) [41,42].
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Figure 2. MiR-1 targets the calcineurin–NFAT signaling pathway; miR-1 plays a protective role in 
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hypertrophic genes, resulting in cardiac hypertrophy. CaM: calmodulin; IP3R: inositol 1,4,5-
triphosphate receptor; LTCC: L-type calcium channel; RYR: ryanodine receptor; SR: sarcoplasmic 
reticulum. 
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cardiomyocyte hypertrophy by downregulating the mRNA and protein levels of calcineurin 
downstream effector NFATC4 [53]. The anti-hypertrophic effect of miR-133a was further revealed in 
the TH-induced hypertrophy rat model. Indeed, decreased levels of miR-133 were reported in this 
animal model, and were thought to be partially mediated by angiotensin II receptor subtype 1 (AT1R) 
[57]. Furthermore, this AT1R appears to also play a role in increasing the expression of two miR-133 
targets, namely calcineurin and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) [57]. 
Taken together, these reports support a role for miR-133 in TH-induced cardiomyocyte hypertrophy. 
Recent evidence hints towards a potential interplay between miR-133a and α1-adrenergic 
receptor (AR)-mediated signaling, thereby affecting calcium-signaling. Indeed, miR-133a 
significantly inhibits norepinephrine (NE)-induced cardiac hypertrophy in vitro by downregulating 
levels of protein kinase C (PKC) and Gq protein [54]. As depicted in Figure 3, NE binds to α1-AR, 
which activates the PKC and phospholipase C (PLC) signaling pathway. PKC leads to the activation 
of transcription factors involved in cardiac hypertrophy through a mitogen-activated protein kinase 
(MAPK) cascade, whereas PLC signaling products—inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG)—activates the calcium signaling pathway and PKC, respectively [58–60]. 
Figure 2. iR-1 targets the calcineurin– F T signaling path ay; iR-1 plays a protective role in
cardiac hypertrophy by decreasing the expression of NFAT. n increase in intracellular calcium ion levels
activates the CaM–calcineurin complex, which dephosphorylates NFAT, leading to its translocation
into the nucleus. In t e cle s, expression of NFAT increases the transcription of hypertrophic ge es,
resulting in cardiac hypertrophy. CaM: calmodulin; IP3R: inositol 1,4,5-triphosphate receptor; LTCC:
L-type calcium channel; RYR: ryanodine receptor; SR: sarcoplasmic reticulum.
Another study investigated the role of miR-1 in cardiac hypertrophy by targeting mitochondrial
calcium uniporter (MCU), the pore-forming subunit of the mitochondrial Ca2+ uniporter complex
(MCUC). MCUC serves a major role in cardiomyocytes stress adaptation by controlling Ca2+ uptake in
the mitochondria. Analysis of human heart biopsies from patients with cardiac hypertrophy revealed
that a decrease in miR-1 levels was associated with an increase in MCU protein content [43].
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MiR-1 can also protect the heart against hypertrophy by regulating the cyclin D kinase
6-retinoblastoma (CDK6-Rb) pathway and levels of thyroid hormone (TH) [44,45]. Hypertrophic rat
cardiomyocytes transfected with miR-1 mimics or CDK6 siRNA inhibit activation of the CDK6-Rb
pathway, which is an important pathway in the regulation of cell cycle progression contributing to
cardiac hypertrophy [44,46].
In a recent study, Diniz et al. [45] report that overexpression of miR-1 prevented TH-induced cardiac
hypertrophy, as indicated by decreased levels of atrial natriuretic peptide (ANP) and alpha-myosin
heavy chain (α-MHC), two markers of cardiac hypertrophy. In addition, TH was found to induce
hypertrophy by targeting histone deacetylase-4 (HDAC4). Indeed, overexpression of miR-1 reduced
the expression of HDAC4, and inhibition of HDAC4 gene helped attenuate TH-induced cardiac
hypertrophy [45].
Downstream targets of miR-1 include the cytoskeleton regulatory protein twinfilin-1 (TWF1) [47].
TWF1 regulates actin dynamics by binding actin monomers, which are known to control various
cell biological processes, such as motility, endocytosis, cell division, and signal transduction [48].
Interestingly, the protein level of TWF1 is inversely related to the expression pattern of miR-1 [47]. Given
that miR-1 negatively regulates cardiac hypertrophy [36], rat cardiomyocytes overexpressing miR-1
displayed reduced cell size and suppressed TWF1 protein expression [47]. Conversely, hypertrophic rat
hearts and phenylephrine (PE)-induced hypertrophic cardiomyocytes showed miR-1 downregulation,
which was associated with upregulated TWF1 and actin protein levels [47].
Insulin-like growth factor-1 (IGF-1) was also reported to be among miR-1 cardiac targets mediating
cardiac hypertrophy [49]. IGF-1 is known to regulate cardiomyocyte size and contractile function [50].
In the transverse aortic constriction (TAC) model [49] and Akt-transgenic animal model [51], repression
of miR-1 was accompanied by an increased IGF-1 protein level and its receptor, IGF-1R. This observation
was reinforced with the clinical demonstration of depressed miR-1 levels in biopsies of patients with
acromegaly, a condition characterized by the overproduction of growth hormone and IGF-1, as well as
increased cardiac myocyte size [49].
3.2. MiR-133a
Similar to miR-1, miR-133a is a muscle-specific miRNA, which exerts an anti-hypertrophic effect
through offsetting multi-targets involved in the calcium signaling, cell growth, and cell development
pathways [52–57]. In this regard, miR-133a transfection reduced cardiac hypertrophy in vivo and
in vitro by downregulating the mRNA and protein expression of calcineurin, a key player in intracellular
Ca2+ regulation [52]. Moreover, miR-133a transfection blocked PE-induced cardiomyocyte hypertrophy
by downregulating the mRNA and protein levels of calcineurin downstream effector NFATC4 [53].
The anti-hypertrophic effect of miR-133a was further revealed in the TH-induced hypertrophy rat
model. Indeed, decreased levels of miR-133 were reported in this animal model, and were thought
to be partially mediated by angiotensin II receptor subtype 1 (AT1R) [57]. Furthermore, this AT1R
appears to also play a role in increasing the expression of two miR-133 targets, namely calcineurin and
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) [57]. Taken together, these reports
support a role for miR-133 in TH-induced cardiomyocyte hypertrophy.
Recent evidence hints towards a potential interplay between miR-133a and α1-adrenergic receptor
(AR)-mediated signaling, thereby affecting calcium-signaling. Indeed, miR-133a significantly inhibits
norepinephrine (NE)-induced cardiac hypertrophy in vitro by downregulating levels of protein kinase
C (PKC) and Gq protein [54]. As depicted in Figure 3, NE binds to α1-AR, which activates the PKC and
phospholipase C (PLC) signaling pathway. PKC leads to the activation of transcription factors involved
in cardiac hypertrophy through a mitogen-activated protein kinase (MAPK) cascade, whereas PLC
signaling products—inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)—activates the calcium
signaling pathway and PKC, respectively [58–60]. Therefore, by targeting PKC and Gq, miR-133a
can inhibit the increase in intracellular Ca2+ levels and the subsequent activation of hypertrophic
transcription factors, such as c-Jun and c-Myc.
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Other miRNAs may also protect the heart against hypertrophy; however, limited research has 
been conducted to investigate their anti-hypertrophic role (Figure 4). Some of these miRNAs mediate 
their effect by regulating factors involved in cardiac development or factors involved in calcium 
signaling and energy metabolism [61–63]. Further research is warranted before the roles of the 
miRNAs can be firmly established. Here, we provide a brief summary of the limited findings 
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Figure 3. The anti-hypertrophic role of miR-133a is mediated by inhibition of Gq-protein and PKC
pathways. Norepinephrine (NE) binds to α1-adrenergic receptor (α1-AR). Upon its activation,
α1-AR couples to G protein, resulting in the activation of PLC. PLC catalyzes the breakdown
of Phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3- and DAG-activating calcium signaling
pathways, as well as a PKC–MAPK pathway, respectively. Both pathways increase the expression
of hypertrophic transcription factors. DAG: diacylglycerol; GDP: guanosine diphosphate; GTP:
guanosine-5’-triphosphate; IP3: inositol 1,4,5-triphosphate; APK: mitogen-activated protein kinase;
PKC: protein kinase C; PLC: phospholipase C.
MiR-133a can also attenuate cardiac hypertrophy by repressing the expression of serum response
factor (SRF) and cyclin D2, both of which exacerbate aberrant cardiomyocyte proliferation and cardiac
dysfunction [55]. Furthermore, others targets of miR-133a include the cardiogenic transcription factor
myocyte enhancer factor 2 (MEF2), as well as serum- and glucocorticoid-responsive kinase-1 (SGK1)
and IGF-1R [56]. Contextually, glucose-induced cardiomyocyte hypertrophy produced upregulation
of MEF2, SGK1, and IGF-1R, as well as reduced expression of miR-133a. Upregulation of the
hypertrophy-associated signaling molecules was attenuated by miR-133a mimics, indicating that MEF2,
SGK1, and IGF-1R act downstream of miR-133a [56].
3.3. Others
Other miRNAs may also protect the heart against hypertrophy; however, limited research has been
conducted to investigate their anti-hypertrophic role (Figure 4). Some of these miRNAs mediate their
effect by regulating factors involved in cardiac development or factors involved in calcium signaling
and energy metabolism [61–63]. Further research is warranted before the roles of the miRNAs can be
firmly established. Here, we provide a brief summary of the limited findings pertaining to the role of
these miRNAs in cardiac hypertrophy.
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Figure 4. Anti-hypertrophic miRNAs ameliorate cardiac hypertrophy by targeting several biological
pathways: iR-10a decreases the expression of T-box5; miR-672-5p and miR-139-5p inhibit c-Jun
expression; miR-135b downregulates CA NA1C (L-type calcium channels); miR-142-3p inhibits SH2B1;
miR-150 represses the xpression of p300. SH2B1: Src homology 2 B adaptor protein 1.
4. icroRNAs that Promote Cardiac Hypertrophy
4.1. MiR-155
MiR-155 promotes cardiac hypertrophy by targeting pro-hypertrophic pathways, such as
inflammation and calcium signaling [64–66]. In one study, miR-155-expressing macrophages appeared
to promote cardiac hypertrophy through the Janus kinase (JAK)/signal transducer and the activator
of the transcription 3 (STAT3) pathway [64]. It has been proposed that the macrophage-expressed
miR-155 induces the inhibition of the macrophage suppressor of cytokine signaling 1 (SOCS1), leading
to the phosphorylation of STAT3 [67]. This phosphorylated STAT3 in macrophages then drives
pro-hypertrophic paracrine signaling to cardiomyocytes, whose STAT3 activity gets potentiated,
thereby leading to cardiac hypertrophy (Figure 5) [64].
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MiR-22 is abundantly expressed in cardiac and skeletal muscles, and it is upregulated during 
myocyte differentiation and cardiac hypertrophy [74]. Similar to miR-155, miR-22 can mediate its 
pro-hypertrophic activity by targeting the calcineurin pathway. In addition, cardiomyocytes 
transfected with miR-22 inhibitors or isolated from miR-22 knockout mice expressed an increase in 
the levels of HDAC4 and sirtuin 1 (SIRT1) [74]. Both HDAC4 and SIRT1 have protective roles in 
relation to cardiac hypertrophy [75,76]. Therefore, one could conclude that miR-22 induces 
hypertrophy by targeting these proteins, but this is yet to be confirmed. 
One of the key pathways implicated in cardiac growth, as well as the promotion of physiological 
and pathological hypertrophy, is the phosphatase and tensin homolog (PTEN). PTEN is a negative 
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Figure 5. MiR-155 targets the JAK/STAT pathway. The macrophage-expressed miR-155 silen es SOCS1
and alleviates its negative regulation of STAT3 phosphorylation. Phosphorylated STAT3 results in
inflammation, leading to pro-hypertrophic paracrine signaling to nearby cardiomyocytes. Activation
of STAT3 in cardiomyocytes pro otes hypertrophy. JAK: Janus kinase; STAT: signal transducer and
activator of transcription; IL-6: interleukin 6; IL-6R: interleukin 6 receptor; SOCS1: suppressor of
cytokine signaling 1; gp130: glycoprotein 130.
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MiR-10a inhibits cardiac hypertrophy by downregulating the expression of T-box5, a transcription
factor involved in cardiac development [61]. Both miR-672-5p and miR-139-5p ameliorate cardiac
hypertrophy in cardiomyocytes by inhibiting the expression of another transcription factor c-Jun,
a subunit of activator protein-1 (AP-1) [68,69]. Similarly, miR-150 mimics were shown to abrogate
glucose-induced cardiomyocyte hypertrophy by repressing the expression of p300, a cofactor for
various hypertrophy-responsive transcription factors [70].
As mentioned earlier, Ca2+ influx promotes cardiac hypertrophy by increasing cardiac contractions
and overload. In particular, L-type Ca2+ channels, encoded by CACNA1C, play a role in the
hypertrophic signaling pathway. The transfection of hypertrophic cardiomyocytes with miR-135b
mimics downregulated CACNA1C mRNA and protein levels and inhibits cardiac hypertrophy,
compared to the control group [62].
Intracellular Ca2+ levels are also regulated by normal mitochondrial function, which is the key
regulator of energy metabolism. MiR-142-3p-attenuated cardiac hypertrophy is overexpressed by
inhibiting the expression of Src homology 2 B adaptor protein 1 (SH2B1), a regulator of energy
metabolism with a pro-hypertrophic role [63]. Interestingly, miR-142-3p overexpression in cardiomyocytes
protects mitochondrial function by increasing mitochondrial density and membrane potential [63].
Although SH2B1 was detected as a direct target for miR-142-3p in cardiac hypertrophy, its role in
miR-142-3p-induced mitochondrial protection is unclear. Because mitochondrial dysfunction plays
a role in promoting cardiac hypertrophy and other cardiac disorders, it is important to address the
protective role of miR-142-3p and other miRNAs in mitochondrial function.
On the other hand, miR-155 contributes to the calcineurin-dependent cardiac hypertrophy pathway,
evident by the reduced heart sizes and β-MHC expression levels in calcineurin/miR155 knockout
mice [65]. Indeed, miR-155-dependent cardiac hypertrophy was found to be mediated by inhibiting
the expression of jumonji AT-rich interactive domain 2 (Jarid2), a key transcriptional regulator of
cardiac development and function with histone demethylase activity [65]. Not surprisingly, mice that
are homozygous knockout for the jumonji gene exhibited defective expression of atrial natriuretic
factor, a hallmark of cardiac hypertrophy [71]. A previous study demonstrated the role of jumonji in
cardiac hypertrophy, by linking it to cell proliferation [72]. Indeed, jumonji represses cell proliferation
by downregulating the expression of the cyclin D1 gene of the cell cycle machinery [72]. Taken
together, one can speculate that Ca2+-dependent pathways and the cell cycle have an interrelated role
in miR-155-related cardiac hypertrophy.
Given that angiotensin II (Ang II) promotes cardiac hypertrophy by binding to cardiac AT1R and
targeting the calcineurin pathway [73], the contribution of miR-155 in the calcineurin-dependent cardiac
hypertrophy pathway was further explored in the Ang II-induced hypertrophy setting. Transfecting
cardiomyocytes with miR-155 inhibitors followed by Ang II treatment resulted in an increase in the
levels of AT1R, intracellular calcium, and calcineurin beta; however, the levels of cardiac hypertrophic
markers,β-MHC and ANP, were not altered [66]. Since miR-155 inhibitors did not decrease hypertrophy,
it has been suggested that inhibition of miR-155 and activation of a calcium signaling pathway may lead
to the apoptosis of some myocardial cells, leading to a reduction of the levels of myocardial hypertrophy
markers [66]. Further research is required to confirm miR-155/calcineurin-induced cardiac hypertrophy.
4.2. MiR-22
MiR-22 is abundantly expressed in cardiac and skeletal muscles, and it is upregulated during
myocyte differentiation and cardiac hypertrophy [74]. Similar to miR-155, miR-22 can mediate its
pro-hypertrophic activity by targeting the calcineurin pathway. In addition, cardiomyocytes transfected
with miR-22 inhibitors or isolated from miR-22 knockout mice expressed an increase in the levels of
HDAC4 and sirtuin 1 (SIRT1) [74]. Both HDAC4 and SIRT1 have protective roles in relation to cardiac
hypertrophy [75,76]. Therefore, one could conclude that miR-22 induces hypertrophy by targeting
these proteins, but this is yet to be confirmed.
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One of the key pathways implicated in cardiac growth, as well as the promotion of physiological and
pathological hypertrophy, is the phosphatase and tensin homolog (PTEN). PTEN is a negative regulator
of the phosphatidyl-3 kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway, an
important player in cardiac function [77]. Studies have shown that miR-22-induced hypertrophy could
involve modulation of PTEN levels. Indeed, overexpression of miR-22 in hypertrophic cardiomyocytes
decreases PTEN protein levels, and increases cell surface area and the expression of cardiac hypertrophy
markers [78]. This negative correlation between miR-22 and PTEN in cardiac hypertrophy was
confirmed in another study, which also showed that treatment with atorvastatin, a cholesterol-lowering
drug with an anti-hypertrophic role, reversed the effects of miR-22 overexpression by upregulating
levels of PTEN [79]. However, these effects of atorvastatin in human patients with cardiac hypertrophy
remain lacking.
4.3. MiR-217
MiR-217 seems to share PTEN with miR-22 with regard to mediating its hypertrophic effect. In this
respect, it was shown that miR-217 overexpression-induced cardiac hypertrophy was counteracted by
restoring PTEN expression, as evident by the decreased hypertrophic markers, ANP and β-MHC [80].
Increased expression of miR-217 has also been shown to be associated with pathological cardiac
hypertrophy, with the implication of euchromatic histone–lysine N-methyltransferases EHMT1 and
EHMT2 [81]. Pathological hypertrophic cues, such as abdominal aortic banding in rats, provoked
augmentation of miR-217 expression and a subsequent reduction in mRNA expression of EHMT1/2,
essential for prenatal heart development and catalysis of histone 3 lysine 9 dimethylation (H3K9me2) [82].
The concomitant reductions in EHMT1/2 and H3K9m2 triggers re-expression of fetal-associated
transcripts, leading ultimately to pathological hypertrophy. Suppression of miR-217 activity prevents
the loss of EHMT1/2 and reverses the induction of hypertrophy [81]. This suggests that miR-217,
by virtue of its ability to modulate methylation, represents an attractive pharmaco-target in the
management/treatment of cardiac hypertrophy.
4.4. MiR-29
MiR-29 is another pro-hypertrophic miRNA that is positively correlated with cardiac
fibrosis [35]. Indeed, inhibition of or genetic deficiency in miR-29 prevents TAC-induced cardiac
hypertrophy, whereas overexpressing miR-29 promotes PE-induced cardiomyocyte hypertrophy [83].
MiR-29-induced cardiac hypertrophy appears to be mediated via indirectly activating the Wnt signaling
pathway through the repression of four inhibitory factors, namely GSK3B, ICAT/CTNNBIP1, HBP1,
and GLIS2 [83].
Like miR-22 and miR-217, miR-29 has been profiled as a PTEN-targeting miRNA [84]. MiR-29
upregulation, provoked by TAC- and AngII-induced models of cardiac hypertrophy, mitigates PTEN
expression. Because PTEN is a negative regulator of the autophagic PI3K/AKT/mTOR cascade, it has
been concluded that miR-29-associated PTEN suppression activates the PI3K/AKT/mTOR system,
thereby abrogating autophagy and promoting cardiac hypertrophy [84].
In contrast, miR-29 has been reported to exert a cardioprotective effect in isoproterenol-induced
cardiac hypertrophy, through the inhibition of a nuclear receptor: peroxisome proliferator-activated
receptor δ (PPARδ) [85]. Another study has hinted to a potential role of miR-29a-3p in attenuating
endothelin-1-induced cardiomyocyte hypertrophy via inhibiting NFATc4 expression. However, this
study was an in vitro study of H9c2 cells [86]. Therefore, further studies are needed to better delineate
the cardiac remodeling role of miR-29.
4.5. MiR-200c
Another pro-hypertrophic miRNA is miR-200c, which is implicated in MAPK signaling and
reactive oxygen species (ROS)/apoptosis pathways [87,88]. Dual-specific phosphatase-1 (DUSP-1)
prevents cardiac hypertrophy by inactivating MAPKs, such as extracellular signal-regulated kinase
(ERK1/2), c-Jun N-terminal kinase (JNK), and p38 [89]. Contextually, DUSP-1 was shown to be a
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target of miR-200c. For instance, miR-200c can induce diabetes-associated cardiac hypertrophy in
high-glucose-treated cardiomyocytes, by downregulating the myocardial expression of DUSP-1 and
thus activating MAPK proteins (Figure 6) [87].
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reduces the expression of DUSP-1, leading to the activati n of MAPKs. MiR-200c targets MLCK and
sarcomere organization. MiR-200c can also promote ROS production and enhance the expression of
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MiR-200c has also been found to promote cardiac hypertrophy by directly targeting myosin light
chain kinase (MLCK), an enzyme involved in cardiovascular physiology and pathophysiology [90].
When miR-200c levels were increased, MLCK levels were reduced [88]. Moreover, in hypertrophic
models, overexpression of miR-200c significantly increased ROS production and apoptosis, as indicated
by the pro-apoptotic markers Bax and caspase-3 [88]. This is in marked contrast to an earlier study,
which suggests that downregulation of miR-200c protects cardiomyocytes from apoptosis [91]. This
apparent discordance could be due to the fact that this latter study was performed in H9c2 cells [91],
while the former one was performed in rats undergoing aortic banding [88], making its findings more
relevant. This calls for further experimentation, to not only study the role of miR-200c in hypertrophy,
but also to delineate the role of MLCK in miR200c-induced cardiac hypertrophy, ROS production, and
the apoptosis of cardiomyocytes (Figure 6).
4.6. Others
In addition to the miRNAs mentioned above, other, less-studied miRNAs promote cardiac
hypertrophy (Figure 7). As noted, an imbalance in the levels of intracellular Ca2+ in the heart disrupts
the functional homeostasis of the cardiovascular system. Other processes, such as autophagy and cell
proliferation, can help maintain functional cardiac homeostasis too [92–94].
Intracellular Ca2+ levels are regulated by an endoplasmic reticulum (ER) chaperone, sigma-1
receptor (Sig-1R). Inhibition of Sig-1R was shown to damage mitochondrial calcium ion mobilization
in cardiomyocytes, thus disrupting intracellular Ca2+ levels and promoting cardiac hypertrophy [95].
In vivo and in vitro models of cardiac hypertrophy show upregulation of miR-297, concomitant with
the downregulation of Sig-1R [95]. In addition, overexpression of miR-297 was found to increase
the protein expression of ER stress markers, such as ATF4, Xbps1, chaperon Grp78, and calreticulin,
accelerating the progression of cardiac hypertrophy [96]. MiR-124 is another miRNA that promotes
cardiac hypertrophy by increasing the expression of ER stress markers; however, its target gene is yet
unknown [92].
A gain-of function study revealed that the hypertrophic effects of miR-23b-5p overexpression
observed in the Ang-II- and TAC-induced cardiac hypertrophy models was mediated via targeting
high-mobility group box 2 (HMGB2) [97], a nuclear protein that regulates gene transcription, DNA
recombination and repair, cell replication, and autophagy [98].
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Figure 7. Pro-hypertrophic miRNAs augment cardiac hypertrophy by targeting different pathways:
(A) miR-297 inhibits the expression of Sig-1R and activates ER stress signaling; (B) miR-23b-5p represses
HMGB2 expression; (C) miR-365 downregulates the expression of Skp2; (D) miR-206 negatively
regulates the expression of Forkhead box protein P1; (E) miR-24 targets p27 and reduces its protein
expression; (F) miR375-3p abrogates the expression of LDHB. ER: endoplasmic reticulum; HMGB2:
high-mobility group box 2; LDHB: lactate dehydrogenase B chain; Sig-1R: sigma-1 receptor; Skp2:
S-phase kinase-associated protein 2.
MiR-365 is known as a positive regulator of cardiac hypertrophy; its overexpression leads to an
increase in the size of cardiomyocytes [99]. In a recent study, miR-365 was revealed to promote the
progression of cardiac pertrophy by down egulating the expression of S-phase, kinase-associated
protein 2 (Skp2), an enzyme involved in the physiological and pathological rocesses of the heart, such
as cardiomyocyte proliferation. Down egulation of Skp2 activates n mTOR signaling pathway, leading
to the suppressi n of autophagy and an increase in cardiac hypertrophy [93]. MiR-206 promoted
Yes-associated protein (YAP)-induced cardiac hypertrophy by negatively regulating the expression of
Forkhead box protein P1 [100], a transcription factor involved in cell cycle progression, proliferation,
and differentiation, as well as in metabolism, survival, and apoptosis [101].
Disruption in the cell cycle and metabolism also promotes cardiac hypertrophy by inducing
cell proliferation [102]. In postnatal cardiac cells, proliferation is translated into an increase in size,
which leads to hypertrophy, rather than an increase in the cardiomyocyte number [103]. MiR-24
was recently found to induce cardiac hypertrophy by reducing the protein expression of p27, a cell
cycle regulator of G0/G1 arrest [102]. By targeting p27, miR-24 promotes the cells in G0/G1 phase
into S phase, increasing cell proliferation and leading to cardiac hypertrophy [104]. In vitro studies
have demonstrated the association between miR-375-3p and cell metabolism. The overexpression of
miR-375-3p in cardiomyocytes inhibits protein expression of lactate dehydrogenase B chain (LDHB),
a regulator of cell metabolism, and promotes cardiac hypertrophy [94].
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5. Concluding Remarks
Cardiac hypertrophy is recognized as a risk predictor of sudden cardiac death. Although it is
effectively managed by pharmacological interventions, its associated pathophysiological changes
are not fully reversed. In addition, experiencing the inevitable treatment-limiting side effects poses
higher incidence of cardiovascular events. Emerging evidence provides the basis, and hence the
raison d’etre, for considering miRNAs as attractive pharmaco-targets in cardiac hypertrophy [105].
The miRNAs tackled in this paper represent the most recently discovered in this field, as well as
some of the most studied ones, a list of which is summarized in Table 1. Based on bioinformatics
analyses, many in vitro and animal studies have successfully identified downstream targets involved
in mediating miRNA regulation of cardiac hypertrophy. However, further studies are needed to
examine a detailed analysis of the underlying mechanisms of miRNA-mediated action. Moreover,
extrapolation from preclinical findings to clinical practice undoubtedly requires extensive studies on
bigger patient cohorts. Additionally, different population traits (age, race, etc.) should be taken into
consideration, in order to define the specificity of the miRNA profile before suggesting its candidacy
for tailored therapy in cardiac hypertrophy. The blue-sky scenario for miRNAs as potential U.S.
Food and Drug Administration (FDA)-approved agents necessitates massive pharmacokinetic testing,
which parallels the traditional drug discovery journey. For instance, systemic delivery approaches,
(intravenous vs. intracardiac), delivery vehicles, and the dosage and duration of the treatment, should
be carefully examined for better target specificity, efficacy, and minimizing off-target effects. Finally,
due to its nucleotide-containing nature, the precipitation of the body’s immune response should be
strictly investigated.
Table 1. Anti- and pro-hypertrophic miRNAs with their targets and the involved signaling pathways.
MiRNAs Targets Signaling Pathway References
Anti-hypertrophic
miR-1
Calcineurin
MCU
CDK6-Rb
HDAC4
TWF1
IGF-1
Calcium signaling
Calcium signaling
CDK-Rb pathway
Transcription
Actin monomer size and
localization
Transcription
[41]
[43]
[44]
[45]
[47]
[49]
miR-133a
Calcineurin
NFATC4
PLC-PKC
SERCA2a
SRF/cyclin D2
IGF-1R/SGK1/MEF2
Calcium signaling
Calcium signaling
Calcium signaling/Transcription
Calcium signaling
Cell cycle
MAPK/ERK
[52]
[53]
[57]
[54]
[55]
[56]
miR-10a T-box5 Transcription [61]
miR-672-5p c-Jun Transcription [68]
miR-139-5p c-Jun Transcription [69]
miR-135b L-type Ca2+ channels Calcium signaling [62]
miR-142-3p SH2B1 Energy balance [63]
miR-150 p300 Transcription [70]
Pro-hypertrophic
miR-155
SOCS1
Jarid2
AT1R
JAK/STAT3
Calcineurin
Calcium signaling
[64]
[65]
[73]
miR-22 HDAC4/SIRT1PTEN
Calcineurin
PI3K/Akt/mTOR
[74]
[78,79]
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Table 1. Cont.
MiRNAs Targets Signaling Pathway References
miR-217 PTENH3K9me2/EHMT1 &2
PI3K/Akt/mTOR
Transcription
[80]
[81]
miR-29
GSK3B,
ICAT/CTNNBIP1, HBP1,
GLIS2
PTEN
Wnt signaling
PI3K/Akt/mTOR
[83]
[84]
miR-200c
DUSP-1
MLCK
Bax/cleaved caspase3
MAPK/JANK/p38
Apoptosis
[87]
[88]
[88]
miR-297
Sig-1R
ATF4, Xbps1, Chaperon
G78, Calreticulin
Mitochondrial Ca2+ mobilization
ER stress signaling pathway
[96]
[96]
miR-124 ER stress markers ER stress signaling pathway [92]
miR- 23b-5p HMGB2 Transcription/autophagy [97]
miR-365 Skp2 mTOR [93]
miR-206 Forkhead box protein P1 Transcription [100]
miR-24 p27 Cell cycle [104]
miR-375-3p LDHB Cell metabolism [94]
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